Chemomab Therapeutics Long Term Debt

Chemomab Therapeutics (CMMB) currently reports a long-term debt of $0 as of March 2026. That compares with $180K in the prior-year period — down 100.0% year over year. Use the charts on this page to explore Chemomab Therapeutics's long-term debt history and peer comparisons.

Chemomab Therapeutics's long-term debt decreased from $180K to $0 — a 100.0% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Chemomab Therapeutics reported $0 in long-term debt as of March 2026. That compares with $180K in the prior-year period — down 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Chemomab Therapeutics, and consider following CMMB for alerts when major investors trade the stock.

Chemomab Therapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CMMB with unrelated industries.